{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:29:00Z","timestamp":1785792540431,"version":"3.56.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s12020-021-02845-4","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T16:03:02Z","timestamp":1628784182000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A practical approach to normocalcemic primary hyperparathyroidism"],"prefix":"10.1007","volume":"74","author":[{"given":"Jos\u00e9 Luis","family":"Mu\u00f1oz de Nova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampedro-Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Huguet-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-2961","authenticated-orcid":false,"given":"M\u00f3nica","family":"Marazuela Azpiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2845_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1210\/jc.2008-1763","volume":"94","author":"JP Bilezikian","year":"2009","unstructured":"J.P. Bilezikian, A.A. Khan, J.T. Potts, Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94, 335\u2013339 (2009). https:\/\/doi.org\/10.1210\/jc.2008-1763","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jocd.2012.12.001","volume":"16","author":"NE Cusano","year":"2013","unstructured":"N.E. Cusano, S.J. Silverberg, J.P. Bilezikian, Normocalcemic primary hyperparathyroidism. J. Clin. Densitom. 16, 33\u201339 (2013). https:\/\/doi.org\/10.1016\/j.jocd.2012.12.001","journal-title":"J. Clin. Densitom."},{"key":"2845_CR3","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2014-1413","volume":"99","author":"JP Bilezikian","year":"2014","unstructured":"J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman, C. Marcocci, J.T. Potts, Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J. Clin. Endocrinol. Metab. 99, 3561\u20133569 (2014). https:\/\/doi.org\/10.1210\/jc.2014-1413","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","volume":"151","author":"SM Wilhelm","year":"2016","unstructured":"S.M. Wilhelm, T.S. Wang, D.T. Ruan, J.A. Lee, S.L. Asa, Q.Y. Duh, G.M. Doherty, M.F. Herrera, J.L. Pasieka, N.D. Perrier, S.J. Silverberg, C.C. Sol\u00f3rzano, C. Sturgeon, M.E. Tublin, R. Udelsman, S.E. Carty, The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 151, 959\u2013968 (2016). https:\/\/doi.org\/10.1001\/jamasurg.2016.2310","journal-title":"JAMA Surg."},{"key":"2845_CR5","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1210\/jc.2014-1414","volume":"99","author":"R Eastell","year":"2014","unstructured":"R. Eastell, M.L. Brandi, A.G. Costa, P. D\u2019Amour, D.M. Shoback, R. Thakker, V: Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3570\u20133579 (2014). https:\/\/doi.org\/10.1210\/jc.2014-1414","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR6","doi-asserted-by":"publisher","first-page":"E1171","DOI":"10.1210\/clinem\/dgaa084","volume":"105","author":"M Schini","year":"2020","unstructured":"M. Schini, R.M. Jacques, E. Oakes, N.F.A. Peel, J.S. Walsh, R. Eastell, Normocalcemic hyperparathyroidism: Study of its prevalence and natural history. J. Clin. Endocrinol. Metab. 105, E1171\u2013E1186 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgaa084","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4158\/EP.12.2.137","volume":"12","author":"JF Aloia","year":"2006","unstructured":"J.F. Aloia, M. Feuerman, J.K. Yeh, Reference range for serum parathyroid hormone. Endocr. Pract. 12, 137\u2013144 (2006). https:\/\/doi.org\/10.4158\/EP.12.2.137","journal-title":"Endocr. Pract."},{"key":"2845_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/cen.13486","volume":"88","author":"C-JL Farrell","year":"2018","unstructured":"C.-J.L. Farrell, L. Nguyen, A.C. Carter, Parathyroid hormone: data mining for age-related reference intervals in adults. Clin. Endocrinol. (Oxf.). 88, 311\u2013317 (2018). https:\/\/doi.org\/10.1111\/cen.13486","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"2845_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cca.2020.05.030","volume":"508","author":"JA Delgado","year":"2020","unstructured":"J.A. Delgado, J.M. Bau\u00e7a, M.I. Pastor, A. Barcel\u00f3, Use of data mining in the establishment of age-adjusted reference intervals for parathyroid hormone. Clin. Chim. Acta 508, 217\u2013220 (2020). https:\/\/doi.org\/10.1016\/j.cca.2020.05.030","journal-title":"Clin. Chim. Acta"},{"key":"2845_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/cen.14315","volume":"93","author":"NB Dawood","year":"2020","unstructured":"N.B. Dawood, K.L. Yan, A. Shieh, M.J. Livhits, M.W. Yeh, A.M. Leung, Normocalcaemic primary hyperparathyroidism: An update on diagnostic and management challenges. Clin. Endocrinol. (Oxf.). 93, 519\u2013527 (2020). https:\/\/doi.org\/10.1111\/cen.14315","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"2845_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.amjsurg.2019.10.032","volume":"219","author":"J G\u00f3mez-Ram\u00edrez","year":"2020","unstructured":"J. G\u00f3mez-Ram\u00edrez, A. G\u00f3mez-Valdazo, P. Luengo, B. Porrero, I. Osorio, S. Rivas, Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? Am. J. Surg. 219, 150\u2013153 (2020). https:\/\/doi.org\/10.1016\/j.amjsurg.2019.10.032","journal-title":"Am. J. Surg."},{"key":"2845_CR12","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1681\/ASN.2007121327","volume":"19","author":"LM Calvi","year":"2008","unstructured":"L.M. Calvi, D.A. Bushinsky, When is it appropriate to order an ionized calcium? J. Am. Soc. Nephrol. 19, 1257\u20131260 (2008). https:\/\/doi.org\/10.1681\/ASN.2007121327","journal-title":"J. Am. Soc. Nephrol."},{"key":"2845_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000491036","volume":"51","author":"S Corbetta","year":"2019","unstructured":"S. Corbetta, Normocalcemic Hyperparathyroidism. Front. Horm. Res. 51, 23\u201339 (2019). https:\/\/doi.org\/10.1159\/000491036","journal-title":"Front. Horm. Res."},{"key":"2845_CR14","doi-asserted-by":"publisher","first-page":"e10391","DOI":"10.1002\/jbm4.10391","volume":"4","author":"G Zavatta","year":"2020","unstructured":"G. Zavatta, B.L. Clarke, Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed? JBMR 4, e10391 (2020). https:\/\/doi.org\/10.1002\/jbm4.10391","journal-title":"JBMR"},{"key":"2845_CR15","doi-asserted-by":"publisher","first-page":"e10417","DOI":"10.1002\/jbm4.10417","volume":"4","author":"A Giustina","year":"2020","unstructured":"A. Giustina, R. Bouillon, N. Binkley, C. Sempos, R.A. Adler, J. Bollerslev, B. Dawson-Hughes, P.R. Ebeling, D. Feldman, A. Heijboer, G. Jones, C.S. Kovacs, M. Lazaretti-Castro, P. Lips, C. Marcocci, S. Minisola, N. Napoli, R. Rizzoli, R. Scragg, J.H. White, A.M. Formenti, J.P. Bilezikian, C. Labrador, Controversies in Vitamin D: A Statement From the Third International Conference. JBMR . 4, e10417 (2020). https:\/\/doi.org\/10.1002\/jbm4.10417","journal-title":"JBMR ."},{"key":"2845_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000486077","volume":"50","author":"C Cipriani","year":"2018","unstructured":"C. Cipriani, J. Pepe, L. Colangelo, S. Minisola, Vitamin D and Secondary Hyperparathyroid States. Front. Horm. Res. 50, 138\u2013148 (2018). https:\/\/doi.org\/10.1159\/000486077","journal-title":"Front. Horm. Res."},{"key":"2845_CR17","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1210\/clinem\/dgaa174","volume":"105","author":"A Palermo","year":"2020","unstructured":"A. Palermo, A.M. Naciu, G. Tabacco, S. Falcone, A. Santonati, D. Maggi, L.D.\u2019 Onofrio, S.I. Briganti, D. Castellitto, A. Casini, C. Pedone, D. Lelli, A. Fabbri, J.P. Bilezikian, N. Napoli, P. Pozzilli, S. Manfrini, R. Cesareo, Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 105, 2609\u20132616 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgaa174","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR18","doi-asserted-by":"publisher","unstructured":"B.C. Silva, N.E. Cusano, J.P. Bilezikian, Primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 101247 (2018). https:\/\/doi.org\/10.1016\/j.beem.2018.09.013","DOI":"10.1016\/j.beem.2018.09.013"},{"key":"2845_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4158\/EP-2019-0325","volume":"26","author":"X Wang","year":"2020","unstructured":"X. Wang, L. Meng, C. Su, S.A. Shapses, Low free (but not total) 25-hydroxyvitamin D levels in subjects with normocalcemic hyperparathyroidism. Endocr. Pract. 26, 174\u2013178 (2020). https:\/\/doi.org\/10.4158\/EP-2019-0325","journal-title":"Endocr. Pract."},{"key":"2845_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.beem.2018.09.009","volume":"32","author":"NE Cusano","year":"2018","unstructured":"N.E. Cusano, C. Cipriani, J.P. Bilezikian, Management of normocalcemic primary hyperparathyroidism. Best. Pract. Res. Clin. Endocrinol. Metab. 32, 837\u2013845 (2018). https:\/\/doi.org\/10.1016\/j.beem.2018.09.009","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"2845_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00423-017-1617-2","volume":"402","author":"J G\u00f3mez-Ram\u00edrez","year":"2017","unstructured":"J. G\u00f3mez-Ram\u00edrez, R. Mihai, Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm. Langenbeck\u2019s Arch. Surg. 402, 1103\u20131108 (2017). https:\/\/doi.org\/10.1007\/s00423-017-1617-2","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"2845_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1530\/EJE-13-0102","volume":"169","author":"C Eller-Vainicher","year":"2013","unstructured":"C. Eller-Vainicher, E. Cairoli, V.V. Zhukouskaya, V. Morelli, S. Palmieri, A. Scillitani, P. Beck-Peccoz, I. Chiodini, Prevalence of subclinical contributors to low bone mineral density and\/or fragility fracture. Eur. J. Endocrinol. 169, 225\u2013237 (2013). https:\/\/doi.org\/10.1530\/EJE-13-0102","journal-title":"Eur. J. Endocrinol."},{"key":"2845_CR23","doi-asserted-by":"publisher","unstructured":"G. Mart\u00ednez D\u00edaz-Guerra, E. J\u00f3dar Gimeno, R. Reyes Garc\u00eda, J.M. G\u00f3mez S\u00e1ez, M. Mu\u00f1oz-Torres, Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up. Endocrinol. Nutr. 60, 456\u2013.e1\u20136 (2013). https:\/\/doi.org\/10.1016\/j.endonu.2013.01.015","DOI":"10.1016\/j.endonu.2013.01.015"},{"key":"2845_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/end.2008.0567","volume":"23","author":"BH Eisner","year":"2009","unstructured":"B.H. Eisner, J. Ahn, M.L. Stoller, Differentiating primary from secondary hyperparathyroidism in stone patients: the \u201cthiazide challenge\u201d. J. Endourol. 23, 191\u2013192 (2009). https:\/\/doi.org\/10.1089\/end.2008.0567","journal-title":"J. Endourol."},{"key":"2845_CR25","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1210\/jc.2015-3964","volume":"101","author":"ML Griebeler","year":"2016","unstructured":"M.L. Griebeler, A.E. Kearns, E. Ryu, P. Thapa, M.A. Hathcock, L.J. Melton, R.A. Wermers, Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J. Clin. Endocrinol. Metab. 101, 1166\u20131173 (2016). https:\/\/doi.org\/10.1210\/jc.2015-3964","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR26","doi-asserted-by":"publisher","unstructured":"G. Mantovani, M. Bastepe, Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat. Rev. Endocrinol. 47, 41. https:\/\/doi.org\/10.1038\/s41574-018-0042-0","DOI":"10.1038\/s41574-018-0042-0"},{"key":"2845_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s42000-018-0069-6","volume":"18","author":"DA Anastasilakis","year":"2019","unstructured":"D.A. Anastasilakis, P. Makras, S.A. Polyzos, A.D. Anastasilakis, Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. Hormones 18, 65\u201370 (2019). https:\/\/doi.org\/10.1007\/s42000-018-0069-6","journal-title":"Hormones"},{"key":"2845_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00774-015-0673-3","volume":"34","author":"MM Tuna","year":"2016","unstructured":"M.M. Tuna, M. \u00c7al\u0131\u015fkan, M. \u00dcnal, T. Demirci, B.A. Do\u011fan, K. K\u00fc\u00e7\u00fckler, M. \u00d6zbek, D. Berker, T. Deliba\u015f\u0131, S. G\u00fcler, Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Miner. Metab. 34, 331\u2013335 (2016). https:\/\/doi.org\/10.1007\/s00774-015-0673-3","journal-title":"J. Bone Miner. Metab."},{"key":"2845_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00423-018-1659-0","volume":"403","author":"E Traini","year":"2018","unstructured":"E. Traini, R. Bellantone, S.E. Tempera, S. Russo, C. De Crea, C.P. Lombardi, M. Raffaelli, Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism? Langenbeck\u2019s Arch. Surg. 403, 317\u2013323 (2018). https:\/\/doi.org\/10.1007\/s00423-018-1659-0","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"2845_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/cen.12569","volume":"82","author":"C Berger","year":"2015","unstructured":"C. Berger, O. Almohareb, L. Langsetmo, D.A. Hanley, C.S. Kovacs, R.G. Josse, J.D. Adachi, J.C. Prior, T. Towheed, K.S. Davison, S.M. Kaiser, J.P. Brown, D. Goltzman, Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin. Endocrinol. (Oxf.). 82, 359\u2013368 (2015). https:\/\/doi.org\/10.1111\/cen.12569","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"2845_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11914-020-00574-7","volume":"18","author":"L Rejnmark","year":"2020","unstructured":"L. Rejnmark, H. Ejlsmark-Svensson, Effects of PTH and PTH hypersecretion on bone: a clinical perspective. Curr. Osteoporos. Rep. 18, 103\u2013114 (2020). https:\/\/doi.org\/10.1007\/s11914-020-00574-7","journal-title":"Curr. Osteoporos. Rep."},{"key":"2845_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11154-019-09507-x","volume":"20","author":"AM Formenti","year":"2019","unstructured":"A.M. Formenti, F. Tecilazich, R. Giubbini, A. Giustina, Risk of vertebral fractures in hypoparathyroidism. Rev. Endocr. Metab. Disord. 20, 295\u2013302 (2019). https:\/\/doi.org\/10.1007\/s11154-019-09507-x","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"2845_CR33","doi-asserted-by":"publisher","unstructured":"A.M. Naciu, G. Tabacco, S. Falcone, G.G. Incognito, I. Chiodini, D. Maggi, C. Pedone, D. Lelli, J.P. Bilezikian, N. Napoli, S. Manfrini, R. Cesareo, A. Palermo, Bone quality, as measured by trabecular bone score in normocalcaemic primary hyperparathyroidism. Endocr. Pract. (2021). https:\/\/doi.org\/10.1016\/j.eprac.2021.04.884","DOI":"10.1016\/j.eprac.2021.04.884"},{"key":"2845_CR34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4158\/EP151055.OR","volume":"22","author":"G D\u00edaz-Soto","year":"2016","unstructured":"G. D\u00edaz-Soto, D. de Luis Rom\u00e1n, O.I. Jauregui, L. Briongo, E. Romero, J.L. P\u00e9rez-Castrill\u00f3n, Trabecular bone score in patients with normocalcemic hyperparathyroidism. Endocr. Pract. 22, 703\u2013707 (2016). https:\/\/doi.org\/10.4158\/EP151055.OR","journal-title":"Endocr. Pract."},{"key":"2845_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/cen.12952","volume":"84","author":"GB Cansu","year":"2016","unstructured":"G.B. Cansu, N. Yilmaz, S. \u00d6zdem, M.K. Balci, G. S\u00fcleymanlar, C. Arici, A. Boz, R. Sari, H.A. Altunba\u015f, Parathyroidectomy in asymptomatic primary hyperparathyroidism reduces carotid intima-media thickness and arterial stiffness. Clin. Endocrinol. (Oxf.). 84, 39\u201347 (2016). https:\/\/doi.org\/10.1111\/cen.12952","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"2845_CR36","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ahj.2013.02.014","volume":"165","author":"AJ van Ballegooijen","year":"2013","unstructured":"A.J. van Ballegooijen, I. Reinders, M. Visser, I.A. Brouwer, Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am. Heart J. 165, 655\u2013664 (2013). https:\/\/doi.org\/10.1016\/j.ahj.2013.02.014. 664.e1\u20135","journal-title":"Am. Heart J."},{"key":"2845_CR37","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1210\/jc.2014-4432","volume":"100","author":"G Chen","year":"2015","unstructured":"G. Chen, Y. Xue, Q. Zhang, T. Xue, J. Yao, H. Huang, J. Liang, L. Li, W. Lin, L. Lin, L. Shi, L. Cai, J. Wen, Is normocalcemic primary hyperparathyroidism harmful or harmless? J. Clin. Endocrinol. Metab. 100, 2420\u20132424 (2015). https:\/\/doi.org\/10.1210\/jc.2014-4432","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1507\/endocrj.EJ15-0392","volume":"63","author":"FY Ozturk","year":"2016","unstructured":"F.Y. Ozturk, S. Erol, M.M. Canat, S. Karatas, I. Kuzu, S.D. Cakir, Y. Altuntas, Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr. J. 63, 111\u2013118 (2016). https:\/\/doi.org\/10.1507\/endocrj.EJ15-0392","journal-title":"Endocr. J."},{"key":"2845_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-019-1093-4","volume":"19","author":"S Beysel","year":"2019","unstructured":"S. Beysel, M. Caliskan, M. Kizilgul, M. Apaydin, S. Kan, M. Ozbek, E. Cakal, Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc. Disord. 19, 1\u20138 (2019). https:\/\/doi.org\/10.1186\/s12872-019-1093-4","journal-title":"BMC Cardiovasc. Disord."},{"key":"2845_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.surg.2019.05.094","volume":"167","author":"O Koubaity","year":"2020","unstructured":"O. Koubaity, D. Mandry, P.L. Nguyen-Thi, F. Bihain, C. Nomine-Criqui, L. Demarquet, V. Croise-Laurent, L. Brunaud, Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery 167, 149\u2013154 (2020). https:\/\/doi.org\/10.1016\/j.surg.2019.05.094","journal-title":"Surgery"},{"key":"2845_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4158\/EP14195.OR","volume":"21","author":"S Temizkan","year":"2015","unstructured":"S. Temizkan, O. Kocak, K. Aydin, A. Ozderya, G. Arslan, N. Yucel, M. Sargin, Normocalcemic hyperparathyroidism and insulin resistance. Endocr. Pract. 21, 23\u201329 (2015). https:\/\/doi.org\/10.4158\/EP14195.OR","journal-title":". Endocr. Pract."},{"key":"2845_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/VHRM.S128084","volume":"13","author":"PN Mesquita","year":"2017","unstructured":"P.N. Mesquita, A.P.D.L. Leite, S. Cris\u00f3stomo, C. das, E.V. Filho, L. Da Cunha Xavier, F. Bandeira, Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. Vasc. Health Risk Manag 13, 225\u2013229 (2017). https:\/\/doi.org\/10.2147\/VHRM.S128084","journal-title":"Vasc. Health Risk Manag"},{"key":"2845_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00223-019-00612-2","volume":"105","author":"LS Bislev","year":"2019","unstructured":"L.S. Bislev, L. Langagergaard R\u00f8dbro, T. Sikj\u00e6r, L. Rejnmark, Effects of elevated parathyroid hormone levels on muscle health, postural stability and quality of life in vitamin D-insufficient healthy women: a cross-sectional study. Calcif. Tissue Int. 105, 642\u2013650 (2019). https:\/\/doi.org\/10.1007\/s00223-019-00612-2","journal-title":"Calcif. Tissue Int."},{"key":"2845_CR44","doi-asserted-by":"publisher","first-page":"115583","DOI":"10.1016\/j.bone.2020.115583","volume":"141","author":"L Voss","year":"2020","unstructured":"L. Voss, M. N\u00f3brega, L. Bandeira, L. Griz, P.A.S. Rocha-Filho, F. Bandeira, Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism. Bone 141, 115583 (2020). https:\/\/doi.org\/10.1016\/j.bone.2020.115583","journal-title":"Bone"},{"key":"2845_CR45","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1210\/jc.2006-2802","volume":"92","author":"H Lowe","year":"2007","unstructured":"H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001\u20133005 (2007). https:\/\/doi.org\/10.1210\/jc.2006-2802","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR46","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4158\/EP15704.OR","volume":"22","author":"H \u0160iprov\u00e1","year":"2016","unstructured":"H. \u0160iprov\u00e1, Z. Fry\u0161\u00e1k, M. Sou\u010dek, Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr. Pract. 22, 294\u2013301 (2016). https:\/\/doi.org\/10.4158\/EP15704.OR","journal-title":"Endocr. Pract."},{"key":"2845_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.amjsurg.2018.09.010","volume":"217","author":"H Yan","year":"2019","unstructured":"H. Yan, N. Calcatera, T.A. Moo-Young, R.A. Prinz, D.J. Winchester, Degree of hypercalcemia correlates with parathyroidectomy but not with symptoms. Am. J. Surg. 217, 437\u2013440 (2019). https:\/\/doi.org\/10.1016\/j.amjsurg.2018.09.010","journal-title":"Am. J. Surg."},{"key":"2845_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.surg.2016.08.054","volume":"161","author":"JY Lim","year":"2017","unstructured":"J.Y. Lim, M.C. Herman, L. Bubis, I. Epelboym, J.D. Allendorf, J.A. Chabot, J.A. Lee, J.H. Kuo, Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 161, 70\u201377 (2017). https:\/\/doi.org\/10.1016\/j.surg.2016.08.054","journal-title":"Surgery"},{"key":"2845_CR49","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1177\/0194599818793879","volume":"159","author":"G Trinh","year":"2018","unstructured":"G. Trinh, E. Rettig, S.I. Noureldine, J.O. Russell, N. Agrawal, A. Mathur, J.D. Prescott, M.A. Zeiger, R.P. Tufano, Surgical management of normocalcemic primary hyperparathyroidism and the impact of intraoperative parathyroid hormone testing on outcome. Otolaryngol. Head. Neck Surg. 159, 630\u2013637 (2018). https:\/\/doi.org\/10.1177\/0194599818793879","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"2845_CR50","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00268-018-4512-2","volume":"42","author":"A Kiriakopoulos","year":"2018","unstructured":"A. Kiriakopoulos, A. Petralias, D. Linos, Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ? World J. Surg. 42, 992\u2013997 (2018). https:\/\/doi.org\/10.1007\/s00268-018-4512-2","journal-title":"World J. Surg."},{"key":"2845_CR51","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s00268-019-05157-x","volume":"44","author":"CE Graves","year":"2020","unstructured":"C.E. Graves, C.M. McManus, J.A. Chabot, J.A. Lee, J.H. Kuo, Biochemical profile affects IOPTH kinetics and cure rate in primary hyperparathyroidism. World J. Surg. 44, 488\u2013495 (2020). https:\/\/doi.org\/10.1007\/s00268-019-05157-x","journal-title":"World J. Surg."},{"key":"2845_CR52","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1210\/jc.2015-2132","volume":"100","author":"F Tassone","year":"2015","unstructured":"F. Tassone, A. Guarnieri, E. Castellano, C. Baffoni, R. Attanasio, G. Borretta, Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 100, 3069\u20133073 (2015). https:\/\/doi.org\/10.1210\/jc.2015-2132","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR53","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/jbmr.3177","volume":"32","author":"K Lundstam","year":"2017","unstructured":"K. Lundstam, A. Heck, K. Godang, C. Mollerup, M. Baranowski, Y. Pernow, T. Aas, O. Hessman, T. Ros\u00e9n, J. Nordenstr\u00f6m, S. Jansson, M. Hellstr\u00f6m, J. Bollerslev, Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH Study). J. Bone Miner. Res. 32, 1907\u20131914 (2017). https:\/\/doi.org\/10.1002\/jbmr.3177","journal-title":"J. Bone Miner. Res."},{"key":"2845_CR54","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1097\/MD.0000000000000931","volume":"94","author":"SP Cheng","year":"2015","unstructured":"S.P. Cheng, J.J. Lee, T.P. Liu, P.S. Yang, S.C. Liu, Y.C. Hsu, C.L. Liu, Quality of life after surgery or surveillance for asymptomatic primary hyperparathyroidism: a meta-analysis of randomized controlled trials. Med. (Baltim.) 94, e931 (2015). https:\/\/doi.org\/10.1097\/MD.0000000000000931","journal-title":"Med. (Baltim.)"},{"key":"2845_CR55","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1245\/s10434-018-6998-0","volume":"26","author":"S Sho","year":"2019","unstructured":"S. Sho, E.J. Kuo, A.C. Chen, N. Li, M.W. Yeh, M.J. Livhits, Biochemical and skeletal outcomes of parathyroidectomy for normocalcemic (incipient) primary hyperparathyroidism. Ann. Surg. Oncol. 26, 539\u2013546 (2019). https:\/\/doi.org\/10.1245\/s10434-018-6998-0","journal-title":"Ann. Surg. Oncol."},{"key":"2845_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.surg.2018.04.065","volume":"165","author":"D Lee","year":"2019","unstructured":"D. Lee, M.D. Walker, H.Y. Chen, J.A. Chabot, J.A. Lee, J.H. Kuo, Bone mineral density changes after parathyroidectomy are dependent on biochemical profile. Surgery 165, 107\u2013113 (2019). https:\/\/doi.org\/10.1016\/j.surg.2018.04.065","journal-title":"Surgery"},{"key":"2845_CR57","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"J. Pepe, C. Cipriani, C. Sonato, O. Raimo, F. Biamonte, S. Minisola, Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur. J. Endocrinol. 177, R297\u2013R308 (2017). https:\/\/doi.org\/10.1530\/EJE-17-0485","journal-title":"Eur. J. Endocrinol."},{"key":"2845_CR58","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1245\/s10434-014-3731-5","volume":"21","author":"C Blanchard","year":"2014","unstructured":"C. Blanchard, M. Mathonnet, F. Sebag, C. Caillard, C. Kubis, D. Drui, E. van Nuvel, C. Ansquer, J.F. Henry, D. Masson, F. Kraeber-Bod\u00e9r\u00e9, J.B. Hardouin, R. Zarnegar, A. Hamy, E. Miralli\u00e9, Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study. Ann. Surg. Oncol. 21, 3534\u20133540 (2014). https:\/\/doi.org\/10.1245\/s10434-014-3731-5","journal-title":"Ann. Surg. Oncol."},{"key":"2845_CR59","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/bjs.10739","volume":"105","author":"S Bannani","year":"2018","unstructured":"S. Bannani, N. Christou, C. Gu\u00e9rin, A. Hamy, F. Sebag, M. Mathonnet, P. Guillot, C. Caillard, C. Blanchard, E. Miralli\u00e9, Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br. J. Surg. 105, 223\u2013229 (2018). https:\/\/doi.org\/10.1002\/bjs.10739","journal-title":"Br. J. Surg."},{"key":"2845_CR60","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/1754-9485.12728","volume":"62","author":"P Cunha-Bezerra","year":"2018","unstructured":"P. Cunha-Bezerra, R. Vieira, F. Amaral, H. Cartaxo, T. Lima, U. Montarroyos, F. Bandeira, Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism. J. Med. Imaging Radiat. Oncol. 62, 493\u2013498 (2018). https:\/\/doi.org\/10.1111\/1754-9485.12728","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"2845_CR61","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/SLA.0b013e31825ffbe1","volume":"257","author":"H Mazeh","year":"2013","unstructured":"H. Mazeh, H. Chen, G. Leverson, R.S. Sippel, Creation of a \u201cWisconsin index\u201d nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann. Surg. 257, 138\u2013141 (2013). https:\/\/doi.org\/10.1097\/SLA.0b013e31825ffbe1","journal-title":"Ann. Surg."},{"key":"2845_CR62","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00423-019-01782-1","volume":"404","author":"E Tr\u00e9bouet","year":"2019","unstructured":"E. Tr\u00e9bouet, S. Bannani, M. Wargny, C. Leux, C. Caillard, F. Kraeber-Bod\u00e9r\u00e9, K. Renaudin, L. Chaillous, \u00c9. Miralli\u00e9, C. Ansquer, Mild sporadic primary hyperparathyroidism: high rate of multiglandular disease is associated with lower surgical cure rate. Langenbeck\u2019s Arch. Surg. 404, 431\u2013438 (2019). https:\/\/doi.org\/10.1007\/s00423-019-01782-1","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"2845_CR63","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.surg.2019.06.043","volume":"167","author":"TK Pandian","year":"2020","unstructured":"T.K. Pandian, C.C. Lubitz, S.H. Bird, L.E. Kuo, A.E. Stephen, Normocalcemic hyperparathyroidism: a collaborative endocrine surgery quality improvement program analysis. Surgery 167, 168\u2013172 (2020). https:\/\/doi.org\/10.1016\/j.surg.2019.06.043","journal-title":"Surgery"},{"key":"2845_CR64","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40618-018-0931-z","volume":"42","author":"I Bossert","year":"2019","unstructured":"I. Bossert, S. Chytiris, M. Hodolic, L. Croce, L. Mansi, L. Chiovato, G. Mariani, G. Trifir\u00f2, PETC\/CT with 18 F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J. Endocrinol. Invest. 42, 419\u2013426 (2019). https:\/\/doi.org\/10.1007\/s40618-018-0931-z","journal-title":"J. Endocrinol. Invest."},{"key":"2845_CR65","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.surg.2003.06.001","volume":"134","author":"DM Carneiro","year":"2003","unstructured":"D.M. Carneiro, C.C. Solorzano, M.C. Nader, M. Ramirez, G.L. Irvin, 3rd: Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 134, 973\u2013981 (2003). https:\/\/doi.org\/10.1016\/j.surg.2003.06.001","journal-title":"Surgery"},{"key":"2845_CR66","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00268-012-1438-y","volume":"36","author":"TJ Wade","year":"2012","unstructured":"T.J. Wade, T.W.F. Yen, A.L. Amin, T.S. Wang, Surgical management of normocalcemic primary hyperparathyroidism. World J. Surg. 36, 761\u2013766 (2012). https:\/\/doi.org\/10.1007\/s00268-012-1438-y","journal-title":"World J. Surg."},{"key":"2845_CR67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrendo.2017.104","volume":"14","author":"MD Walker","year":"2018","unstructured":"M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14, 115\u2013125 (2018). https:\/\/doi.org\/10.1038\/nrendo.2017.104","journal-title":"Nat. Rev. Endocrinol."},{"key":"2845_CR68","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4065\/82.3.351","volume":"82","author":"B Farford","year":"2007","unstructured":"B. Farford, R.J. Presutti, T.J. Moraghan, Nonsurgical management of primary hyperparathyroidism. Mayo Clin. Proc. 82, 351\u2013355 (2007). https:\/\/doi.org\/10.4065\/82.3.351","journal-title":"Mayo Clin. Proc."},{"key":"2845_CR69","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"M.T. Drake, B.L. Clarke, S. Khosla, Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032\u20131045 (2008). https:\/\/doi.org\/10.4065\/83.9.1032","journal-title":"Mayo Clin. Proc."},{"key":"2845_CR70","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1210\/jc.2003-030908","volume":"89","author":"AA Khan","year":"2004","unstructured":"A.A. Khan, J.P. Bilezikian, A.W.C. Kung, M.M. Ahmed, S.J. Dubois, A.Y.Y. Ho, D. Schussheim, M.R. Rubin, A.M. Shaikh, S.J. Silverberg, T.I. Standish, Z. Syed, Z.A. Syed, Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 3319\u20133325 (2004). https:\/\/doi.org\/10.1210\/jc.2003-030908","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR71","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","volume":"26","author":"R Cesareo","year":"2015","unstructured":"R. Cesareo, E. Di Stasio, F. Vescini, G. Campagna, R. Cianni, V. Pasqualini, F. Romitelli, F. Grimaldi, S. Manfrini, A. Palermo, Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos. Int. 26, 1295\u20131302 (2015). https:\/\/doi.org\/10.1007\/s00198-014-3000-2","journal-title":"Osteoporos. Int."},{"key":"2845_CR72","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1210\/jc.2016-2481","volume":"102","author":"G Tsvetov","year":"2017","unstructured":"G. Tsvetov, D. Hirsch, I. Shimon, C. Benbassat, H. Masri-Iraqi, A. Gorshtein, D. Herzberg, T. Shochat, I. Shraga-Slutzky, T. Diker-Cohen, Thiazide treatment in primary hyperparathyroidism-a new indication for an old medication? J. Clin. Endocrinol. Metab. 102, 1270\u20131276 (2017). https:\/\/doi.org\/10.1210\/jc.2016-2481","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2845_CR73","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","volume":"87","author":"S Brardi","year":"2015","unstructured":"S. Brardi, G. Cevenini, T. Verdacchi, G. Romano, R. Ponchietti, Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch. Ital. di Urol. Androl. 87, 66\u201371 (2015). https:\/\/doi.org\/10.4081\/aiua.2015.1.66","journal-title":"Arch. Ital. di Urol. Androl."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02845-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T06:58:54Z","timestamp":1633676334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02845-4","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"13 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}